$2.6m in non-dilutive capital funding secured
Filed with ASX · · 2 pages · English
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Patient recruitment for world first TRP-8803 trial underway
- Binge Eating Disorder Trial receives Human Ethics approval
- TRP-8803 BED trial to commence with Swinburne this quarter
- Appendix 4D and Half Year Report for period 31 Dec 2024
- Positive interim results in Phase 2a TRP-8802 IBS trial
Later from Entropy Neurodynamics
- Landmark EEG Biomarker Agreement for Precision Psychiatry
- Appendix 4E and 2025 Annual Report
- First patient enrolled in Binge Eating Disorder Trial
- Trading Halt
- $6.1m in new funding to accelerate clinical development
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics